Literature DB >> 25470087

Long-acting injectable antipsychotics: an underutilized treatment option.

Stephan Heres1.   

Abstract

In this issue, Kane and colleagues report on the efficacy of aripiprazole long-acting injection (LAI) in the treatment of an acute episode of schizophrenia. At 10 weeks of treatment, both psychopathology and functioning were improved in patients treated with aripiprazole compared to placebo, with an acceptable tolerability and safety profile. The outcomes suggest that aripiprazole long-acting is a viable treatment option for patients experiencing an acute episode of schizophrenia. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25470087     DOI: 10.4088/JCP.14com09541

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program.

Authors:  Maria Ruiza Yee; Eduardo Espiridon; Adeolu O Oladunjoye; Udema Millsaps; Anish Vora; Nailah Harvey
Journal:  Cureus       Date:  2021-04-14

Review 2.  New Antipsychotic Medications in the Last Decade.

Authors:  Mehak Pahwa; Ahmad Sleem; Omar H Elsayed; Megan Elizabeth Good; Rif S El-Mallakh
Journal:  Curr Psychiatry Rep       Date:  2021-11-29       Impact factor: 5.285

Review 3.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 4.  Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.

Authors:  Enrico Biagi; Enrico Capuzzi; Fabrizia Colmegna; Alessandra Mascarini; Giulia Brambilla; Alessandra Ornaghi; Jacopo Santambrogio; Massimo Clerici
Journal:  Adv Ther       Date:  2017-04-05       Impact factor: 3.845

5.  Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection.

Authors:  Heather M Fitzgerald; Jason Shepherd; Hollie Bailey; Mia Berry; Jack Wright; Maxine Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-21       Impact factor: 2.570

6.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.